Cerebral Venous Thrombosis Medication
- Author: W Alvin McElveen, MD; Chief Editor: Helmi L Lutsep, MD more...
Heparin should be considered seriously in the management of cerebral venous thrombosis (CVT), with subsequent conversion to warfarin as maintenance therapy suggested. Subcutaneous low ̶ molecular-weight heparin (Lovenox) also has been used in patients with venous sinus thrombosis.
Thrombolytic therapy may be effective in CVT, but all studies so far describe its use only with local instillation by microcatheter or direct instillation at the time of surgical thrombectomy.
These medications are used to prevent propagation of the clot to more extensive areas of the cerebral venous system. Studies indicate a tendency toward better outcome in patients treated with anticoagulant therapy than in those who are not treated with anticoagulants. In Einhaupl's study, even patients with cerebral hemorrhage appeared to benefit from anticoagulation.
Heparin increases the action of antithrombin III, leading to inactivation of coagulation enzymes thrombin, factor Xa, and factor IXa. Thrombin is the enzyme that is most sensitive to inactivation by heparin.
Because heparin is not absorbed from the GI tract, it must be given parenterally. When given intravenously, its effect is immediate. Metabolism of heparin is complex; rapid zero-order metabolism is followed by slower first-order renal clearance. The saturable phase of heparin clearance is thought to be due to binding to endothelial cell receptors and macrophages in which it is depolymerized. Zero-order process is saturable, leading to an increase in half-life from 30 minutes with a low dose bolus to 150 minutes with a high dose bolus. Weight-based protocol is now often used for dosing. When choosing this therapy, the risks of its contraindications must be weighed against the potential benefits of the drug.
Enoxaparin is a low-molecular-weight heparin (LMWH) produced by partial chemical or enzymatic depolymerization of unfractionated heparin (UFH). It binds to antithrombin III, enhancing its therapeutic effect. The heparin-antithrombin III complex binds to and inactivates activated factor X (Xa) and factor II (thrombin). LMWH differs from UFH by having a higher ratio of anti–factor Xa to anti–factor IIa.
Enoxaparin does not actively lyse thrombi but is able to inhibit further thrombogenesis. It prevents reaccumulation of clot after spontaneous fibrinolysis. Its advantages include intermittent dosing and a decreased requirement for monitoring. Heparin anti–factor Xa levels may be obtained if needed to establish adequate dosing. There is no point in checking the aPTT; the drug has a wide therapeutic window, and aPTT does not correlate with anticoagulant effect.
Warfarin interferes with the action of vitamin K, a cofactor essential for converting precursor proteins into factors II, VII, IX, and X. Warfarin does not affect the activity of coagulation factors synthesized prior to exposure to warfarin. Depletion of these mature factors by normal metabolism must occur before the therapeutic effects of the newly synthesized factors can be seen; thus, warfarin may take several days to become effective.
The dose of warfarin administered is influenced by differences in absorption, metabolism, and hemostatic responses to given concentrations; the dose must be monitored closely by following the prothrombin time (PT) and international normalized ratio (INR). Higher initial doses do not appear to improve the time required to achieve therapeutic levels but do increase the bleeding risk.
The expert opinion is that warfarin treatment should be maintained for 3-6 months, but no randomized, placebo-controlled trials have addressed this issue.
These agents cause the lysis of clots. All studies concerning the use of these agents in cerebral venous thrombosis (CVT) involve either direct instillation into the sinus at the time of surgery or the use of microcatheters to reach the venous sinus.
Alteplase is a biosynthetic form of human tissue plasminogen activator. Tissue plasminogen activator exerts an effect on the fibrinolytic system that results in the conversion of plasminogen to plasmin. Plasmin degrades fibrin, fibrinogen, and procoagulant factors V and VIII.
Alteplase is not given as an IV infusion to treat CVT. Refer the patient to a facility with the expertise to perform venous sinus catheterization.
Reteplase is a recombinant tPA that forms plasmin after facilitating cleavage of endogenous plasminogen. In clinical trials, it has been shown to be comparable with tPA in achieving patency at 90 minutes. Heparin and aspirin are usually given concomitantly and afterwards.
Tenecteplase is a modified version of alteplase that is made by substituting 3 amino acids. It has a longer half-life than alteplase and thus can be given as a single bolus infused over 5 seconds (as opposed to the 90 minutes required for alteplase). It appears to cause less non–intracranial bleeding than alteplase but carries a comparable risk of intracranial bleeding and stroke.
Base the dose on the patient's weight. Initiate treatment as soon as possible after the onset of AMI symptoms. Because tenecteplase contains no antibacterial preservatives, it must be reconstituted immediately before use.
[Guideline] Bushnell C, McCullough LD, Awad IA, Chireau MV, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. National Guideline Clearinghouse. Available at http://guideline.gov/content.aspx?id=47871&search=cerebral+venous+thrombosis. Accessed: November 21, 2014.
Cesarman-Maus G, Cantú-Brito C, Barinagarrementeria F, Villa R, Reyes E, Sanchez-Guerrero J. Autoantibodies against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis. Stroke. 2011 Feb. 42(2):501-3. [Medline].
Canhão P, Batista P, Falcão F. Lumbar puncture and dural sinus thrombosis--a causal or casual association?. Cerebrovasc Dis. 2005. 19(1):53-6. [Medline].
Ennaifer R, Moussa A, Mouelhi L, et al. Cerebral venous sinus thrombosis as presenting feature of ulcerative colitis. Acta Gastroenterol Belg. 2009 Jul-Sep. 72(3):350-3. [Medline].
Towbin A. The syndrome of latent cerebral venous thrombosis: its frequency and relation to age and congestive heart failure. Stroke. 1973 May-Jun. 4(3):419-30. [Medline].
Daif A, Awada A, al-Rajeh S, et al. Cerebral venous thrombosis in adults. A study of 40 cases from Saudi Arabia. Stroke. 1995 Jul. 26(7):1193-5. [Medline].
Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin. 1992 Feb. 10(1):87-111. [Medline].
Galarza M, Gazzeri R. Cerebral venous sinus thrombosis associated with oral contraceptives: the case for neurosurgery. Neurosurg Focus. 2009 Nov. 27(5):E5. [Medline].
Smith AG, Cornblath WT, Deveikis JP. Local thrombolytic therapy in deep cerebral venous thrombosis. Neurology. 1997 Jun. 48(6):1613-9. [Medline].
Ferro JM, Crassard I, Coutinho JM, Canhão P, Barinagarrementeria F, Cucchiara B. Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke. 2011 Oct. 42(10):2825-31. [Medline].
Ferro JM, Lopes MG, Rosas MJ, et al. Long-Term Prognosis of Cerebral Vein and Dural Sinus Thrombosis. results of the venoport study. Cerebrovasc Dis. 2002. 13(4):272-8. [Medline].
Buccino G, Scoditti U, Patteri I, et al. Neurological and cognitive long-term outcome in patients with cerebral venous sinus thrombosis. Acta Neurol Scand. 2003 May. 107(5):330-5. [Medline].
Flores-Barragan JM, Hernandez-Gonzalez A, Gallardo-Alcaniz MJ, Del Real-Francia MA, Vaamonde-Gamo J. [Clinical and therapeutic heterogeneity of cerebral venous thrombosis: a description of a series of 20 cases.]. Rev Neurol. 2009 Dec 1-15. 49(11):573-6. [Medline].
Oppenheim C, Domigo V, Gauvrit JY, et al. Subarachnoid hemorrhage as the initial presentation of dural sinus thrombosis. AJNR Am J Neuroradiol. 2005 Mar. 26(3):614-7. [Medline].
Farb RI, Vanek I, Scott JN, et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology. 2003 May 13. 60(9):1418-24. [Medline].
Wasay M, Kojan S, Dai AI, Bobustuc G, Sheikh Z. Headache in Cerebral Venous Thrombosis: incidence, pattern and location in 200 consecutive patients. J Headache Pain. 2010 Apr. 11(2):137-9. [Medline].
Tardy B, Tardy-Poncet B, Viallon A, et al. D-dimer levels in patients with suspected acute cerebral venous thrombosis. Am J Med. 2002 Aug 15. 113(3):238-41. [Medline].
Lalive PH, de Moerloose P, Lovblad K, et al. Is measurement of D-dimer useful in the diagnosis of cerebral venous thrombosis?. Neurology. 2003 Oct 28. 61(8):1057-60. [Medline].
Kosinski CM, Mull M, Schwarz M, et al. Do normal D-dimer levels reliably exclude cerebral sinus thrombosis?. Stroke. 2004 Dec. 35(12):2820-5. [Medline].
Ozsvath RR, Casey SO, Lustrin ES, et al. Cerebral venography: comparison of CT and MR projection venography. AJR Am J Roentgenol. 1997 Dec. 169(6):1699-707. [Medline].
Mas JL, Meder JF, Meary E, Bousser MG. Magnetic resonance imaging in lateral sinus hypoplasia and thrombosis. Stroke. 1990 Sep. 21(9):1350-6. [Medline].
Adams WM, Laitt RD, Beards SC, et al. Use of single-slice thick slab phase-contrast angiography for the diagnosis of dural venous sinus thrombosis. Eur Radiol. 1999. 9(8):1614-9. [Medline].
Ayanzen RH, Bird CR, Keller PJ, et al. Cerebral MR venography: normal anatomy and potential diagnostic pitfalls. AJNR Am J Neuroradiol. 2000 Jan. 21(1):74-8. [Medline].
Medel R, Monteith SJ, Crowley RW, Dumont AS. A review of therapeutic strategies for the management of cerebral venous sinus thrombosis. Neurosurg Focus. 2009 Nov. 27(5):E6. [Medline].
Bentley JN, Figueroa RE, Vender JR. From presentation to follow-up: diagnosis and treatment of cerebral venous thrombosis. Neurosurg Focus. 2009 Nov. 27(5):E4. [Medline].
Einhaupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet. 1991 Sep 7. 338(8767):597-600. [Medline].
de Bruijn SF, Stam J, Vandenbroucke JP. Increased risk of cerebral venous sinus thrombosis with third- generation oral contraceptives. Cerebral Venous Sinus Thrombosis Study Group. Lancet. 1998 May 9. 351(9113):1404. [Medline].
Rahman M, Velat GJ, Hoh BL, Mocco J. Direct thrombolysis for cerebral venous sinus thrombosis. Neurosurg Focus. 2009 Nov. 27(5):E7. [Medline].
Ekseth K, Bostrom S, Vegfors M. Reversibility of severe sagittal sinus thrombosis with open surgical thrombectomy combined with local infusion of tissue plasminogen activator: technical case report. Neurosurgery. 1998 Oct. 43(4):960-5. [Medline].
Alonso-Canovas A, Masjuan J, Gonzalez-Valcarcel J, et al. [Cerebral venous thrombosis: when etiology makes the difference.]. Neurologia. 2009 Sep. 24(7):439-45. [Medline].
Benamer HT, Bone I. Cerebral venous thrombosis: anticoagulants or thrombolyic therapy?. J Neurol Neurosurg Psychiatry. 2000 Oct. 69(4):427-30. [Medline].
Cipri S, Gangemi A, Campolo C, et al. High-dose heparin plus warfarin administration in non-traumatic dural sinuses thrombosis. A clinical and neuroradiological study. J Neurosurg Sci. 1998 Mar. 42(1):23-32. [Medline].
D'Alise MD, Fichtel F, Horowitz M. Sagittal sinus thrombosis following minor head injury treated with continuous urokinase infusion. Surg Neurol. 1998 Apr. 49(4):430-5. [Medline].
Davis KR, Kistler JP, Buonanno FS. Clinical neuroimaging approaches to cerebrovascular diseases. Neurol Clin. 1984 Nov. 2(4):655-65. [Medline].
Gold Standard Multimedia. Urokinase, Altevase, Streptokinase, Heparin, Warfarin. Clinical Pharmacology. 2000. Available at:http://cp.gsm.com/. [Full Text].
Gomez CR, Misra VK, Terry JB, et al. Emergency endovascular treatment of cerebral sinus thrombosis with a rheolytic catheter device. J Neuroimaging. 2000 Jul. 10(3):177-80. [Medline].
Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res. 2003 Jul 15. 109 Suppl 1:S9-15. [Medline].
Jacobs K, Moulin T, Bogousslavsky J, et al. The stroke syndrome of cortical vein thrombosis. Neurology. 1996 Aug. 47(2):376-82. [Medline].
Leys D, Cordonnier C. Cerebral venous thrombosis: Update on clinical manifestations, diagnosis and management. Ann Indian Acad Neurol. 2008. 11:79-87. [Full Text].
Meyer-Lindenberg A, Quenzel EM, Bierhoff E, et al. Fatal cerebral venous sinus thrombosis in heparin-induced thrombotic thrombocytopenia. Eur Neurol. 1997. 37(3):191-2. [Medline].
Zweifler RM. Management of acute stroke. South Med J. 2003 Apr. 96(4):380-5. [Medline].